Effects of a bitter substance, denatonium benzoate, on pancreatic hormone secretion
This study investigated the effect of the bitter substance, denatonium benzoate (DB), on hormone secretion from mouse pancreatic islets and INS-1 832/13 cells. DB (0.5-1mM) augmented insulin secretion at both 2.8mM and 16.7mM glucose. This effect was no longer present at 5mM DB likely due to greater levels of cellular apoptosis. DB-stimulated insulin secretion involved closure of the KATP channel, activation of T2R signalling in beta-cells and intra-islet GLP-1 release. DB also enhanced glucagon and somatostatin secretion, but the underlying mechanism was less clear. Together, this study demonstrates that the bitter substa...
Source: Am J Physiol Endocri... - March 13, 2024 Category: Endocrinology Authors: Weikun Huang Stephanie E O'Hara Cong Xie Ning Liu Christopher K Rayner Lisa M Nicholas Tongzhi Wu Source Type: research
The Prostaglandin E < sub > 2 < /sub > EP3 Receptor Has Disparate Effects on Islet Insulin Secretion and Content in β-cells in a High Fat Diet-induced Mouse Model of Obesity
Am J Physiol Endocrinol Metab. 2024 Mar 13. doi: 10.1152/ajpendo.00061.2023. Online ahead of print.ABSTRACTSignaling through Prostaglandin E2 EP3 receptor (EP3) actively contributes to the β-cell dysfunction of type 2 diabetes (T2D). In T2D models, full-body EP3 knockout mice have a significantly worse metabolic phenotype than wild-type controls due to hyperphagia and severe insulin resistance resulting from loss of EP3 in extra-pancreatic tissues, masking any potential beneficial effects of EP3 loss in the β-cell. We hypothesized β-cell-specific EP3 knockout (EP3 βKO) mice would be protected from high-fat diet (HFD)-i...
Source: Am J Physiol Endocri... - March 13, 2024 Category: Endocrinology Authors: Joshua C Neuman Austin Reuter Kathryn A Carbajal Michael D Schaid Grant Kelly Kelsey Connors Cecilia Kaiser Joshua Krause Liam D Hurley Angela Olvera Dawn Belt Davis Jaclyn A Wisinski Maureen Gannon Michelle E Kimple Source Type: research
Metabolic-Associated Fatty Liver Disease is Characterized by a Post-Oral Glucose Load Hyperinsulinemia in Individuals with Mild Metabolic Alterations
Am J Physiol Endocrinol Metab. 2024 Mar 13. doi: 10.1152/ajpendo.00294.2023. Online ahead of print.ABSTRACTMetabolic-associated fatty liver disease (MAFLD) has been identified as risk factor of incident type 2 diabetes (T2D), but the underlying postprandial mechanisms remains unclear. We compared the glucose metabolism, insulin resistance, insulin secretion and insulin clearance post-oral glucose tolerance test (OGTT) between individuals with and without MAFLD. We included 50 individuals with a BMI between 25-40 kg/m2 and ≥1 metabolic alteration: increased fasting triglycerides or insulin, plasma glucose 5.5-6.9 mmol/L, ...
Source: Am J Physiol Endocri... - March 13, 2024 Category: Endocrinology Authors: Th éo Gignac Gabrielle Tr épanier Marion Pradeau Arianne Morissette Anne-Laure Agrinier Eric Larose Julie Marois Genevi ève Pilon Claudia Gagnon Marie-Claude Vohl Andr é Marette Anne-Marie Carreau Source Type: research
Incretin and Glucagon Receptor Polypharmacology in Chronic Kidney Disease
Am J Physiol Endocrinol Metab. 2024 Mar 13. doi: 10.1152/ajpendo.00374.2023. Online ahead of print.ABSTRACTChronic kidney disease (CKD) is a debilitating condition associated with significant morbidity and mortality. In recent years, the kidney effects of incretin-based therapies, particularly glucagon-like peptide-1 receptor agonists (GLP-1RAs), have garnered substantial interest in the management of type 2 diabetes (T2D) and obesity. This review delves into the intricate interactions between the kidney, GLP-1RAs, and glucagon, shedding light on their mechanisms of action and potential kidney benefits. Both GLP-1 and gluc...
Source: Am J Physiol Endocri... - March 13, 2024 Category: Endocrinology Authors: Brandon E McFarlin Kevin L Duffin Anish Konkar Source Type: research
The anti-emetic actions of GIP receptor agonism
Am J Physiol Endocrinol Metab. 2024 Mar 13. doi: 10.1152/ajpendo.00330.2023. Online ahead of print.ABSTRACTNausea and vomiting are primitive aspects of mammalian physiology and behavior that ensure survival. Unfortunately, both are ubiquitously present side effects of drug treatments for many chronic diseases with negative consequences on pharmacotherapy tolerance, quality of life, and prognosis. One of the most critical clinical examples is the profound emesis and nausea that occur in patients undergoing chemotherapy, which continue to be among the most distressing side effects, even with the use of modern anti-emetic med...
Source: Am J Physiol Endocri... - March 13, 2024 Category: Endocrinology Authors: Tito Borner Bart C De Jonghe Matthew R Hayes Source Type: research
Brown Adipose Tissue Metabolism in Women is Dependent on Ovarian Status
Am J Physiol Endocrinol Metab. 2024 Mar 13. doi: 10.1152/ajpendo.00077.2024. Online ahead of print.ABSTRACTIn rodents, loss of estradiol (E2) reduces brown adipose tissue (BAT) metabolic activity. Whether E2 impacts BAT activity in women is not known. BAT oxidative metabolism was measured in premenopausal (N=27, 35±9 years, body mass index (BMI) = 26.0±5.3 kg/m2) and postmenopausal (N=25, 51±8 years, BMI = 28.0±5.0 kg/m2) women at room temperature (RT) and during acute cold exposure using [11C]-acetate with positron emission tomography coupled with computed tomography (PET/CT). BAT glucose uptake was also measured duri...
Source: Am J Physiol Endocri... - March 13, 2024 Category: Endocrinology Authors: Denis P Blondin Francois Haman Tracy M Swibas Sophie Hogan-Lamarre Lauralyne Dumont Jolan Guertin Gabriel Richard Quentin Weissenburger Kerry L Hildreth Irene E Schauer Shelby Panter Liza Wayland Andr é C Carpentier Yubin Miao Jiayun Shi Elizabeth Jaruez Source Type: research
Effects of a bitter substance, denatonium benzoate, on pancreatic hormone secretion
This study investigated the effect of the bitter substance, denatonium benzoate (DB), on hormone secretion from mouse pancreatic islets and INS-1 832/13 cells. DB (0.5-1mM) augmented insulin secretion at both 2.8mM and 16.7mM glucose. This effect was no longer present at 5mM DB likely due to greater levels of cellular apoptosis. DB-stimulated insulin secretion involved closure of the KATP channel, activation of T2R signalling in beta-cells and intra-islet GLP-1 release. DB also enhanced glucagon and somatostatin secretion, but the underlying mechanism was less clear. Together, this study demonstrates that the bitter substa...
Source: Am J Physiol Endocri... - March 13, 2024 Category: Endocrinology Authors: Weikun Huang Stephanie E O'Hara Cong Xie Ning Liu Christopher K Rayner Lisa M Nicholas Tongzhi Wu Source Type: research
The Prostaglandin E < sub > 2 < /sub > EP3 Receptor Has Disparate Effects on Islet Insulin Secretion and Content in β-cells in a High Fat Diet-induced Mouse Model of Obesity
Am J Physiol Endocrinol Metab. 2024 Mar 13. doi: 10.1152/ajpendo.00061.2023. Online ahead of print.ABSTRACTSignaling through Prostaglandin E2 EP3 receptor (EP3) actively contributes to the β-cell dysfunction of type 2 diabetes (T2D). In T2D models, full-body EP3 knockout mice have a significantly worse metabolic phenotype than wild-type controls due to hyperphagia and severe insulin resistance resulting from loss of EP3 in extra-pancreatic tissues, masking any potential beneficial effects of EP3 loss in the β-cell. We hypothesized β-cell-specific EP3 knockout (EP3 βKO) mice would be protected from high-fat diet (HFD)-i...
Source: Am J Physiol Endocri... - March 13, 2024 Category: Endocrinology Authors: Joshua C Neuman Austin Reuter Kathryn A Carbajal Michael D Schaid Grant Kelly Kelsey Connors Cecilia Kaiser Joshua Krause Liam D Hurley Angela Olvera Dawn Belt Davis Jaclyn A Wisinski Maureen Gannon Michelle E Kimple Source Type: research
Metabolic-Associated Fatty Liver Disease is Characterized by a Post-Oral Glucose Load Hyperinsulinemia in Individuals with Mild Metabolic Alterations
Am J Physiol Endocrinol Metab. 2024 Mar 13. doi: 10.1152/ajpendo.00294.2023. Online ahead of print.ABSTRACTMetabolic-associated fatty liver disease (MAFLD) has been identified as risk factor of incident type 2 diabetes (T2D), but the underlying postprandial mechanisms remains unclear. We compared the glucose metabolism, insulin resistance, insulin secretion and insulin clearance post-oral glucose tolerance test (OGTT) between individuals with and without MAFLD. We included 50 individuals with a BMI between 25-40 kg/m2 and ≥1 metabolic alteration: increased fasting triglycerides or insulin, plasma glucose 5.5-6.9 mmol/L, ...
Source: Am J Physiol Endocri... - March 13, 2024 Category: Endocrinology Authors: Th éo Gignac Gabrielle Tr épanier Marion Pradeau Arianne Morissette Anne-Laure Agrinier Eric Larose Julie Marois Genevi ève Pilon Claudia Gagnon Marie-Claude Vohl Andr é Marette Anne-Marie Carreau Source Type: research
Incretin and Glucagon Receptor Polypharmacology in Chronic Kidney Disease
Am J Physiol Endocrinol Metab. 2024 Mar 13. doi: 10.1152/ajpendo.00374.2023. Online ahead of print.ABSTRACTChronic kidney disease (CKD) is a debilitating condition associated with significant morbidity and mortality. In recent years, the kidney effects of incretin-based therapies, particularly glucagon-like peptide-1 receptor agonists (GLP-1RAs), have garnered substantial interest in the management of type 2 diabetes (T2D) and obesity. This review delves into the intricate interactions between the kidney, GLP-1RAs, and glucagon, shedding light on their mechanisms of action and potential kidney benefits. Both GLP-1 and gluc...
Source: Am J Physiol Endocri... - March 13, 2024 Category: Endocrinology Authors: Brandon E McFarlin Kevin L Duffin Anish Konkar Source Type: research
The anti-emetic actions of GIP receptor agonism
Am J Physiol Endocrinol Metab. 2024 Mar 13. doi: 10.1152/ajpendo.00330.2023. Online ahead of print.ABSTRACTNausea and vomiting are primitive aspects of mammalian physiology and behavior that ensure survival. Unfortunately, both are ubiquitously present side effects of drug treatments for many chronic diseases with negative consequences on pharmacotherapy tolerance, quality of life, and prognosis. One of the most critical clinical examples is the profound emesis and nausea that occur in patients undergoing chemotherapy, which continue to be among the most distressing side effects, even with the use of modern anti-emetic med...
Source: Am J Physiol Endocri... - March 13, 2024 Category: Endocrinology Authors: Tito Borner Bart C De Jonghe Matthew R Hayes Source Type: research
Brown Adipose Tissue Metabolism in Women is Dependent on Ovarian Status
Am J Physiol Endocrinol Metab. 2024 Mar 13. doi: 10.1152/ajpendo.00077.2024. Online ahead of print.ABSTRACTIn rodents, loss of estradiol (E2) reduces brown adipose tissue (BAT) metabolic activity. Whether E2 impacts BAT activity in women is not known. BAT oxidative metabolism was measured in premenopausal (N=27, 35±9 years, body mass index (BMI) = 26.0±5.3 kg/m2) and postmenopausal (N=25, 51±8 years, BMI = 28.0±5.0 kg/m2) women at room temperature (RT) and during acute cold exposure using [11C]-acetate with positron emission tomography coupled with computed tomography (PET/CT). BAT glucose uptake was also measured duri...
Source: Am J Physiol Endocri... - March 13, 2024 Category: Endocrinology Authors: Denis P Blondin Francois Haman Tracy M Swibas Sophie Hogan-Lamarre Lauralyne Dumont Jolan Guertin Gabriel Richard Quentin Weissenburger Kerry L Hildreth Irene E Schauer Shelby Panter Liza Wayland Andr é C Carpentier Yubin Miao Jiayun Shi Elizabeth Jaruez Source Type: research
Effects of a bitter substance, denatonium benzoate, on pancreatic hormone secretion
This study investigated the effect of the bitter substance, denatonium benzoate (DB), on hormone secretion from mouse pancreatic islets and INS-1 832/13 cells. DB (0.5-1mM) augmented insulin secretion at both 2.8mM and 16.7mM glucose. This effect was no longer present at 5mM DB likely due to greater levels of cellular apoptosis. DB-stimulated insulin secretion involved closure of the KATP channel, activation of T2R signalling in beta-cells and intra-islet GLP-1 release. DB also enhanced glucagon and somatostatin secretion, but the underlying mechanism was less clear. Together, this study demonstrates that the bitter substa...
Source: Am J Physiol Endocri... - March 13, 2024 Category: Endocrinology Authors: Weikun Huang Stephanie E O'Hara Cong Xie Ning Liu Christopher K Rayner Lisa M Nicholas Tongzhi Wu Source Type: research
The Prostaglandin E < sub > 2 < /sub > EP3 Receptor Has Disparate Effects on Islet Insulin Secretion and Content in β-cells in a High Fat Diet-induced Mouse Model of Obesity
Am J Physiol Endocrinol Metab. 2024 Mar 13. doi: 10.1152/ajpendo.00061.2023. Online ahead of print.ABSTRACTSignaling through Prostaglandin E2 EP3 receptor (EP3) actively contributes to the β-cell dysfunction of type 2 diabetes (T2D). In T2D models, full-body EP3 knockout mice have a significantly worse metabolic phenotype than wild-type controls due to hyperphagia and severe insulin resistance resulting from loss of EP3 in extra-pancreatic tissues, masking any potential beneficial effects of EP3 loss in the β-cell. We hypothesized β-cell-specific EP3 knockout (EP3 βKO) mice would be protected from high-fat diet (HFD)-i...
Source: Am J Physiol Endocri... - March 13, 2024 Category: Endocrinology Authors: Joshua C Neuman Austin Reuter Kathryn A Carbajal Michael D Schaid Grant Kelly Kelsey Connors Cecilia Kaiser Joshua Krause Liam D Hurley Angela Olvera Dawn Belt Davis Jaclyn A Wisinski Maureen Gannon Michelle E Kimple Source Type: research
Metabolic-Associated Fatty Liver Disease is Characterized by a Post-Oral Glucose Load Hyperinsulinemia in Individuals with Mild Metabolic Alterations
Am J Physiol Endocrinol Metab. 2024 Mar 13. doi: 10.1152/ajpendo.00294.2023. Online ahead of print.ABSTRACTMetabolic-associated fatty liver disease (MAFLD) has been identified as risk factor of incident type 2 diabetes (T2D), but the underlying postprandial mechanisms remains unclear. We compared the glucose metabolism, insulin resistance, insulin secretion and insulin clearance post-oral glucose tolerance test (OGTT) between individuals with and without MAFLD. We included 50 individuals with a BMI between 25-40 kg/m2 and ≥1 metabolic alteration: increased fasting triglycerides or insulin, plasma glucose 5.5-6.9 mmol/L, ...
Source: Am J Physiol Endocri... - March 13, 2024 Category: Endocrinology Authors: Th éo Gignac Gabrielle Tr épanier Marion Pradeau Arianne Morissette Anne-Laure Agrinier Eric Larose Julie Marois Genevi ève Pilon Claudia Gagnon Marie-Claude Vohl Andr é Marette Anne-Marie Carreau Source Type: research
